SLSHIGH SIGNALFINANCIAL10-K

SLS completed a major capital raise with cash increasing 417% to $71.8M and stockholders' equity surging 649% to $70.9M, while advancing multiple drug programs including positive Phase 2 AML trial results.

The massive improvement in financial position eliminates near-term funding concerns and provides runway for expanded R&D operations, evidenced by the 69% increase in R&D spending. The positive clinical milestones, including FDA guidance to advance SLS009 into first-line AML therapy and exceeding efficacy thresholds, position the company well for potential regulatory approvals and partnership opportunities.

Comparing 2026-03-19 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

SLS dramatically strengthened its balance sheet with cash surging from $13.9M to $71.8M and stockholders' equity increasing 649% to $70.9M, indicating a successful equity raise. The company reduced liabilities by 25% while increasing R&D investment by 69% to $15.7M, demonstrating disciplined capital allocation toward drug development. This financial transformation provides substantial runway for operations and eliminates immediate dilution or funding pressures.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+648.8%
$9.5M$70.9M

Equity base grew 648.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+417%
$13.9M$71.8M

Cash position surged 417% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+360.7%
$16.3M$75.2M

Current assets grew 360.7% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+303.2%
$19.4M$78.3M

Asset base grew 303.2% — expansion through organic growth, acquisitions, or capital deployment.

Capital Expenditure
Cash Flow
-96.1%
$153K$6K

Capex reduced 96.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
+68.9%
$9.3M$15.7M

R&D investment increased 68.9% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
-50.1%
$3.7M$1.8M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Debt
Balance Sheet
+34.6%
$8.2M$11.0M

Debt increased 34.6% — substantial leverage increase; assess whether deployed for growth or covering losses.

Current Liabilities
Balance Sheet
-26.2%
$9.5M$7.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-25%
$10.0M$7.5M

Liabilities reduced 25% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-20
ADDED
In December 2025, we announced that our contract research organization informed us that the pooled number of events was 72 as of December 26, 2025.
We remain blinded to all efficacy and survival data outcomes and, as no outcomes analyses were performed and no statistical penalty has been incurred, this one-time update on the aggregate number of events does not impact future statistical analyses.
GPS was granted Orphan Drug Designations, or ODD, from the FDA, as well as orphan medicines designations from the European Medicines Agency, or EMA, in AML, malignant pleural mesothelioma, or MPM, and multiple myeloma, or MM, as well as Fast Track designations for AML, MPM, and MM from the FDA.
In December 2024, we announced positive data from the first 3 cohorts in the Phase 2a trial.
In July 2025, we announced that the Phase 2 trial of SLS009 in r/r AML met all primary endpoints and received FDA guidance to advance into a first-line therapy study.
+7 more — sign up free →
REMOVED
In December 2023, we announced that we had commenced a binding arbitration proceeding against 3D Medicines to resolve a dispute regarding, among other things, the trigger and payment of relevant milestone payments due to us under the 3D Medicines Agreement.
In addition to safety and tolerability of SLS009 in combination with aza/ven, the efficacy endpoints are complete response composite rate and duration of response.
Additional endpoints include event free survival, overall survival, and pharmacokinetic and pharmacodynamic assessments.
In the fourth quarter of 2023, we completed enrollment in the 45 mg (safety) dose cohort in the Phase 2a study and reported positive initial topline data.
At that time, we also commenced enrollment in the 60 mg dose cohort with patients randomized to one of two groups, 60 mg fixed dose once weekly or 30 mg fixed twice weekly.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →